"I don't think ASSURE wasn't sufficiently powered to do that analysis.  And they would have needed some a priori hypothesis and prior evidence to justify that subgroup analysis."

Right on KayakerBC. Probably a lot more patients and money (in addition to a priori hypotheses) would have been required to increase the sample size of each subgroup and properly power ASSURE. The BETonMACE subgroup analyses will be incredibly revealing to determine in what subgroups (if any) apabetalone is acting to elicit a MACE reducing benefit.

BearDownAZ